Treatment for elderly patients with higher-risk myelodysplastic syndromes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 1/2 trial aims to evaluate the safety and efficacy of a conditioning regimen combining Venetoclax and Azacytidine followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in elderly patients diagnosed with higher-risk myelodysplastic syndromes (MDS). The study will assess overall survival, progression-free survival, and the incidence of complications such as graft-versus-host disease over a two-year period post-transplantation. The trial will include patients who meet specific clinical criteria and are willing to adhere to the study protocol.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.
* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.
* The patient should be diagnosed with higher risk MDS according to the standard criteria of the World Health Organization (WHO).

Exclusion Criteria:

* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.
* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.

Where it's running

• Navy General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Liren Qian, PhD — Navy General Hospital, Beijing
• Study coordinator: Liren Qian, PhD
• Email: qlr2007@126.com
• Phone: +861066947192

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bexmarilimab with Azacitidine vs Placebo with Azacitidine in Adults with Higher-Risk MDS

  This phase 2b study tests whether adding bexmarilimab to azacitidine helps adults with newly diagnosed higher-risk myelodysplastic syndromes compared with azacitidine alone.

  Recruiting Phase 2 Faron Pharmaceuticals Ltd · Duarte, California and 34 other locations · NCT07672769

• AZD3632, alone or with other anticancer agents, for advanced blood cancers driven by HOX overexpression

  This trial will test whether the oral drug AZD3632, given alone or with the antifungal posaconazole, is safe and helps control relapsed or refractory AML, ALL, or high-risk MDS that have KMT2A rearrangements, NPM1 mutations, or other genotypes causing HOX overexpression.

  Recruiting at 20 sites Phase 1/2 AstraZeneca · Decatur, Illinois and 29 other locations · NCT07155226

• Investigating REM-422 for patients with higher risk MDS or relapsed AML

  This study is testing a new oral medication called REM-422 to see if it can help people with higher risk myelodysplastic syndromes or relapsed acute myeloid leukemia feel better and fight their cancer.

  Recruiting at 9 sites Phase 1 Remix Therapeutics · Duarte, California and 8 other locations · NCT06297941

• Evaluating AK117 with Azacitidine for higher-risk Myelodysplastic Syndromes

  This study is testing if a new treatment combining AK117 with azacitidine can help people recently diagnosed with higher-risk myelodysplastic syndromes feel better compared to standard treatment.

  Recruiting at 15 sites Phase 2 Akeso · Los Angeles, California and 14 other locations · NCT06196203

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.